|
|
|
|
|
Foscarnet
drug data and news
Foscarnet drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Foscarnet | ||
| Brand Names/Synonyms | Carboxyphosphonic Acid; Dihydroxyphosphinecarboxylic Acid Oxide; FOSCARNET; FOSCARNET SODIUM; Formic Acid, Phosphono-; Forscarnet Sodium; Foscarmet; Foscarnet; Foscarnet Sodium; Foscavir; PFA; Phgosphonocarboxylic Acid; Phosphonoformate; Phosphonoformic Acid; Triapten | ||
| Indication | For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro. | ||
| Mechanism Of Action | Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. | ||
| Foscarnet News (When available) |
Hospira Reports First-Quarter 2006 Results May 9, 2006 ADVENTRX to Present Positive Thiovir Antiviral Activity Results Apr 26, 2006 | ||
| Dosage Forms | INJECTION | ||
| Drug_Category | Antivirals; Reverse Transcriptase Inhibitors; ATC:J05AD01 | ||
| Absorption | Poorly absorbed after oral administration (bioavailability from 12 to 22%). | ||
| Interactions |
-->Interactions for Foscarnet: A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described. Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia; one patient died with severe hypocalcemia. Toxicity associated with concomitant use of aerosolized pentamidine has not been reported. Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient. Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir. Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution. Ganciclovir The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease. | ||
| Toxicity | Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment. | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | phosphonomethanoicacid | ||
| Chemical Formula | CH3O5P | ||
| Molecular Weight | 126.005 g/mol | ||
| Smiles String | C(=O)(O)P(=O)(O)O | ||
| Melting Point | 88.06 °C | ||
| Water Solubility | Complete | ||
| State | Solid (white, crystalline powder) | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Renal | ||
| Half Life | 3.3 to 6.8 hours | ||
| Protein Binding [%] | 14-17% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Foscarnet.html http://www.rxlist.com/cgi/generic2/foscarnet.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00669 | ||
| CAS Registry Number | 63585-09-1 | ||
| KEGG Compound ID | C07623 | ||
| PubChem ID | SID:595937 | ||
| PharmGKB ID | PA449706 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |